Peru bans imports from five pharmaceutical firms after substandard cancer drugs probe
As reported by The Bureau of Investigative Journalism, back in March the outlet revealed early impact from its investigation into bad cancer drugs that had been imported by Peru. The Bureau had found that the Peruvian government had been forced to destroy more than 100,000 vials of chemo drugs after discovering they had failed quality tests.
In response to the story, Peru’s drug regulator said it was going to inspect 26 overseas drug factories and check that they hold a certificate, called a GMP, which guarantees drug production meets international standards. None of the five companies found to have sold bad drugs to Peru – Beta Drugs, United Biotech, Kwality Pharmaceuticals, Vee Excel and Naprod Life Sciences – were GMP-certified.
The director of Peru’s drug regulator, Digemid, also told The Bureau’s co-reporters at Salud con Lupa that they expected to complete the certification of more than 180 plants within the year. “From then on, no medication will be allowed to enter the country without GMP certification issued by Digemid,” the director said.
Now The Bureau reports that all of the pharmaceutical companies investigated failed to obtain a GMP certification. This means that, as of May this year, they can no longer supply medicines to Peru.
The Bureau’s investigation showed that patients were being denied cancer treatment not just because of a shortage of drugs or a lack of funding, but also because of dodgy drug makers and lax regulation.
In Peru, this placed the safety of generic medicines – which are vital treatments, especially for the most vulnerable patients – firmly on the public agenda. It forced authorities to explain what they would do to close the certification gap, and helped revive the legislative debate around Digemid reform.
Deputy Editor
Read more similar news:
Comments:
comments powered by Disqus
